Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results Presented at the American Transplant Congress in Boston, MA, May 15-19, 2004 (abstracts 250461 and 251150).
Show full item record

This item appears in the following Collection(s)

Search Deep Blue

Advanced Search

Browse by

My Account


Coming Soon

MLibrary logo